ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
- Shareholders' equity, 2025
- $789M
- YoY, 2025
- +1,076.3%
- 5-year CAGR
- −4.9%
- 10-year CAGR
- −4.6%
Shareholders' equity
Shareholders' equity by fiscal year
| Period | Equity | YoY |
|---|---|---|
| 2025 | $789M | +1,076.3% |
| 2024 | $67M | — |
| 2023 | −$221M | — |
| 2022 | −$158M | — |
| 2021 | $588M | −42.1% |
| 2020 | $1.0B | −29.4% |
| 2019 | $1.4B | +10.5% |
| 2018 | $1.3B | −26.3% |
| 2017 | $1.8B | +92.0% |
| 2016 | $920M | −27.2% |
| 2015 | $1.3B | +35.1% |
| 2014 | $936M | +246.3% |
| 2013 | $270M | +101.7% |
| 2012 | $134M | +13.6% |
| 2011 | $118M | −25.4% |
| 2010 | $158M | −11.1% |
| 2009 | $178M | −12.0% |
| 2008 | $202M | — |